Peregrine Pharmaceuticals (PPHM) : Zacks Investment Research ranks Peregrine Pharmaceuticals (PPHM) as 3, which is a Hold recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 3 research analysts is 1.67, which indicates as a Buy.
Peregrine Pharmaceuticals (PPHM) : 3 Wall Street analysts covering Peregrine Pharmaceuticals (PPHM) believe that the average level the stock could reach for the short term is $1. The maximum price target given is $2 and the minimum target for short term is around $1, hence the standard deviation is calculated at $0.5.
Peregrine Pharmaceuticals (NASDAQ:PPHM): After opening at $0.3825, the stock dipped to an intraday low of $0.375 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $0.3833 and the buying power remained strong till the end. The stock closed at $0.3829 for the day, a gain of 0.53% for the day session. The total traded volume was 493,789. The stocks close on the previous trading day was $0.3809.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its phosphatidylserine (PS) targeting agent, PGN65, and its brain cancer therapy Cotara. Bavituximab is the Companys therapeutic PS-targeting antibody. PGN650 is its PS-targeting imaging agent. The Company is evaluating the bavituximab investigator-sponsored trials (IST) in front-line, HER2-negative metastatic breast cancer, liver cancer, rectal adenocarcinoma and advanced melanoma. It is also evaluating PGN650 imaging in multiple solid tumor types. The Company`s Impavido biomanufacturing subsidiary Avid Bioservices, Inc., provides commercial and clinical manufacturing services for the Company and third-party clients.